BRIEF published on 10/10/2025 at 22:16, 10 months 1 day ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 10 months 1 day ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 10 months 1 day ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 10 months 25 days ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 10 months 25 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 10 months 25 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 10 months 25 days ago Informations privilégiées / Autres communiqués Teva et Medincell présenteront les résultats de phase 3 de l'Olanzapine LAI à Psych Congress 2025, préparant le lancement du traitement de la schizophrénie avec Teva Schizophrénie Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 11 months ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
BRIEF published on 09/12/2025 at 07:35, 11 months ago Medincell nomme trois nouveaux membres au conseil d'administration Innovation Biopharmaceutique Direction Nominations Au Conseil D'administration Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 11 months ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
Published on 08/12/2026 at 15:42, 6 hours 10 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 6 hours 10 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 6 hours 52 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 7 hours 7 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 21:05, 47 minutes ago Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Published on 08/12/2026 at 19:57, 1 hour 55 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 2 hours 15 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 4 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 4 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 3 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 3 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
